These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36505747)

  • 1. Structure-based virtual screening identified novel FOXM1 inhibitors as the lead compounds for ovarian cancer.
    Zhou ZY; Han XY; Sun LQ; Li SY; Xue ST; Li ZR
    Front Chem; 2022; 10():1058256. PubMed ID: 36505747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
    Westhoff GL; Chen Y; Teng NNH
    Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
    Westhoff GL; Chen Y; Teng NNH
    Int J Gynecol Cancer; 2017 Jun; 27(5):887-894. PubMed ID: 28498253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosmarinic Acid Methyl Ester Regulates Ovarian Cancer Cell Migration and Reverses Cisplatin Resistance by Inhibiting the Expression of Forkhead Box M1.
    Lim SH; Nam KH; Kim K; Yi SA; Lee J; Han JW
    Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33053721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based virtual screening towards the discovery of novel FOXM1 inhibitors.
    Xie ZS; Zhou ZY; Sun LQ; Yi H; Xue ST; Li ZR
    Future Med Chem; 2022 Feb; 14(4):207-219. PubMed ID: 34809496
    [No Abstract]   [Full Text] [Related]  

  • 7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer.
    Chen Y; Ruben EA; Rajadas J; Teng NNH
    Bioorg Med Chem; 2015 Aug; 23(15):4576-4582. PubMed ID: 26164623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circ_0025033 deficiency suppresses paclitaxel resistance and malignant development of paclitaxel-resistant ovarian cancer cells by modulating the miR-532-3p/FOXM1 network.
    Huang H; Yan L; Zhong J; Hong L; Zhang N; Luo X
    Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):275-286. PubMed ID: 35196944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
    Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
    PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer.
    Zhou J; Wang Y; Wang Y; Yin X; He Y; Chen L; Wang W; Liu T; Di W
    PLoS One; 2014; 9(5):e96989. PubMed ID: 24824601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
    Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
    Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule targeting FOXM1 DNA binding domain exhibits anti-tumor activity in ovarian cancer.
    Zhang Z; Xue ST; Gao Y; Li Y; Zhou Z; Wang J; Li Z; Liu Z
    Cell Death Discov; 2022 Jun; 8(1):280. PubMed ID: 35680842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Virtual Screening Identifying Novel FOXM1 Inhibitors as the Lead Compounds for Glioblastoma.
    Swati K; Srivastava R; Agrawal K; Panda SP; Parkash A; Kumar D; Chen H
    Recent Pat Anticancer Drug Discov; 2024 May; ():. PubMed ID: 38756075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased FOXM1 Expression by Cisplatin Inhibits Paclitaxel-Related Apoptosis in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma (OSCC) Cell Lines.
    Choi HS; Kim YK; Hwang KG; Yun PY
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXM1 confers acquired cisplatin resistance in breast cancer cells.
    Kwok JM; Peck B; Monteiro LJ; Schwenen HD; Millour J; Coombes RC; Myatt SS; Lam EW
    Mol Cancer Res; 2010 Jan; 8(1):24-34. PubMed ID: 20068070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
    Fan Q; Cai Q; Xu Y
    Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells.
    Hou Y; Zhu Q; Li Z; Peng Y; Yu X; Yuan B; Liu Y; Liu Y; Yin L; Peng Y; Jiang Z; Li J; Xie B; Duan Y; Tan G; Gulina K; Gong Z; Sun L; Fan X; Li X
    Cell Death Dis; 2017 Mar; 8(3):e2659. PubMed ID: 28277541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
    Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
    J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.